Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01024608 · ClinicalTrials.gov registry record · Phase 3
Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR)
A Phase 3 study, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 3
- Development phase
- 340
- Enrollment target
NCT01024608: Completed Phase 3 study, sponsored by Teva Branded Pharmaceutical Products R&D.
NCT01024608 is a Phase 3 study that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 340 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (56% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01024608, a Phase 3 study, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 340 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the efficacy and safety of an investigational nasal aerosol compared with placebo nasal aerosol in the treatment of seasonal allergic rhinitis.
Primary Outcome
Participants recorded the severity of their nasal symptoms (sneezing, runny nose, nasal itching and nasal congestion) over the past 12 hours (prior to the assessment) twice daily (AM and PM) using the following scale: 0=absent (no sign/symptom present); 1=mild (sign/symptom present, easily tolerated); 2=moderate (definite awareness of sign/symptom, bothersome but tolerable); 3=severe (hard to tolerate, interfere with daily activities and/or sleeping). The rTNSS (sum of 4 symptom scores) ranges
Interventions
- DRUG Beclomethasone dipropionate
- DRUG Placebo Nasal Aerosol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 340 participants |
| Start Date | 2009-12-31 |
| Est. Completion | 2010-02-28 |
| Phase | Phase 3 |
What the finished NCT01024608 record still lists
NCT01024608 is an interventional study that assigns participants to a tested intervention. The registered 340 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (56% lower).
The record links to 0 conditions, and to 2 interventions - of which Beclomethasone dipropionate is the first listed.
NCT01024608 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01024608 about?
NCT01024608 is a clinical study titled "Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR)". The purpose of the study is to assess the efficacy and safety of an investigational nasal aerosol compared with placebo nasal aerosol in the treatment of seasonal allergic rhinitis.
What is the current status of trial NCT01024608?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 340 participants. The study started on 2009-12-31. Estimated completion is 2010-02-28.
What interventions are being tested in trial NCT01024608?
The interventions under investigation include: Beclomethasone dipropionate (DRUG), Placebo Nasal Aerosol (DRUG).
Who is sponsoring clinical trial NCT01024608?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01024608's enrollment target sits among peer trials
340 1053rd of 2000 higher than 945 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04176172 · 340 participants · Phase 3
Optimizing Tobacco Use Treatment for PLWHA
- NCT04545424 · 340 participants · Phase 2
Trial of Therapeutic Hypothermia in Patients With ARDS
- NCT04806958 · 340 participants · NA
The PulsePoint Study
- NCT05323409 · 340 participants · NA
Improving Comprehensive Care of Cancer Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI